Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegasys and Copegus in Iranian Thalassemic Patients with HCV
NCT00707850Phase 4Completed
- Sponsor
- Baqiyatallah University of Medical Sciences
- Start
- May 2007
- Primary completion
- Sep 2009
- Modality
- Orthosteric Ligands, Cytokines & Interferons, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, open-label trial of interferon alfa and ribavirin in hepatitis C (HCV), sponsored by Baqiyatallah University of Medical Sciences. Primary endpoints: Early Virologic Response at 12 weeks and End of Treatment Response at 48 weeks. Started May 2007; status: completed.
02
Drugs
interferon alfaribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00707850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00707850.